Daniel Weisdorf, MD, will work closely with the CTSI executive leadership team to oversee the institute's operations. He assumes responsibilities from Jeffrey Miller, MD, who recently stepped down to accept the National Cancer Institute Outstanding Investigator Award and its related work.
Dr. Weisdorf's clinical and research interests are in application of blood marrow transplant therapies for hematologic malignancies as well as extensive study of the clinical complications of transplantation including opportunistic infections and graft versus host disease (GVHD).
Dr. Weisdorf is Professor of Medicine, Chief of the Division of Hematology, Oncology and Transplantation, and Director of the Adult Blood and Marrow Transplant Program. He also provides leadership for clinical trial activity in the Department of Medicine as Associate Chair for Clinical Research and co-leads the Transplant Biology and Therapy Program of the Masonic Cancer Center.
Previously, he served as the Scientific Director of the National Marrow Donor Program and currently is Senior Research Advisor for the Center for International Blood and Marrow Transplant Research, and Scientific Director for the Acute Leukemia Committee of the Center for International Blood and Marrow Transplant Research. He is the University of Minnesota Principal Investigator and former Steering Committee chair of the NIH-sponsored Blood and Marrow Transplant Clinical Trials Network.
In 1975, Dr. Weisdorf received his M.D. from the Chicago Medical School and received Internal Medicine training at Michael Reese Hospitals in Chicago. He was a Fellow at the University of Minnesota in Hematology and Medical Oncology and is Board certified in both disciplines.
As Deputy Director, Dr. Weisdorf will coordinate efforts and efficiency models between CTSI and schools, departments and institutes/centers within the University to achieve excellence in clinical research.